Technology | Breast Density | November 12, 2015

FDA Clears VolparaDensity 3.1 Breast Density Assessment With ACR BI-RADS 5th Edition

Company will demonstrate latest version of breast density assessment software, other advances to quantitative breast imaging suite at RSNA 2015

VolparaDensity 3.1, breast density assessment, FDA approval, BI-RADS Fifth Edition, RSNA 2015

Image courtesy of Volpara Solutions

November 12, 2015 — Volpara Solutions announced that it has received a new 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its VolparaDensity breast imaging software.

Originally cleared for use by the FDA in 2010, the new clearance covers VolparaDensity version 3.1, which has been specifically designed to correlate to the new Fifth Edition of the Breast Imaging-Reporting and Data System (BI-RADS) Atlas recently issued by the American College of Radiology (ACR). The 5th Edition Atlas was updated to require “an overall assessment of the volume of attenuating tissues in the breast, to help indicate the relative possibility that a lesion could be obscured … and that the sensitivity of examination thereby may be compromised by dense breast tissue.” Development of Volpara’s new software included a reader study which was used to optimize VolparaDensity performance to the BI-RADS 5th Edition.

Volpara will showcase VolparaDensity 3.1 software and other new advances to its suite of quantitative breast imaging tools at the 2015 Radiology Society of North America (RSNA) meeting, Nov. 29-Dec. in Chicago.

Because of its volumetric approach, VolparaDensity goes beyond measurement of dense tissue area, and actually measures the compressed thickness and volume of dense tissue to truly show when small regions of “focal density” present a masking risk. VolparaDensity results have been clinically validated in independent studies to correlate to mammography sensitivity.

Volpara has also developed a detailed discussion of the changes that have been made to VolparaDensity to reflect the new ACR BI-RADS Atlas 5th Edition, including significant input from the Volpara customer base, study of the literature, reader study results and research using in-house Volpara databases.

Breast density has not only been linked to an increased risk of breast cancer, it also dramatically impacts early detection. Several large studies have confirmed that as density increases the accuracy of mammography decreases. According to a study published in the New England Journal of Medicine, 35 percent of breast cancer goes undetected by mammography in women with dense breasts and density masks appearance of tumors. Since both dense breast tissue and cancer appear white on a mammogram, it is analogous to looking for a snowball in a snow storm.

Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity helps radiologists objectively assess density from digital mammography and tomosynthesis images to determine which women might benefit from additional imaging. Highly correlated to breast magnetic resonance (MR) assessments, VolparaDensity automatically generates an objective measurement of volumetric breast density correlated to the American College of Radiology (ACR) BI-RADS breast density categories.

For more information: www.volparasolutions.com

Related Content

Right mediolateral oblique (MLO) mammograms for different women with the same breast thickness but varying breast density.

Right mediolateral oblique (MLO) mammograms for different women with the same breast thickness but varying breast density.

News | Breast Imaging | July 30, 2021
July 30, 2021 — Volpara Health, a global health technology software leader providing an integrated breast care platfo
Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an agreement with Invitae Corporation, a leader in medical genetics, to bring Invitae's genetic testing services to Volpara's customers in the United States. 
News | Breast Imaging | July 29, 2021
July 29, 2021 — Volpara Health, a global health technology software leader providing an...
Videos | Artificial Intelligence | July 22, 2021
This is an overview of trends and technologies in radiology...
This change will be debuted at HIMSS 2021, and Vital will be exhibiting as Canon Medical for the first time
News | Information Technology | July 22, 2021
July 22, 2021 — Canon Medical Systems Corpora
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...
According to ARRS’ American Journal of Roentgenology (AJR), return to routine screening for BI-RADS 3 lesions on supplemental automated whole-breast US (ABUS) substantially reduces the recall rate, while being unlikely to result in adverse outcome

Normal right mediolateral oblique (A) and craniocarudal (B) view screening mammograms demonstrate density C breasts. Coronal (C), transverse (D), and reconstructed lateral (E) views from supplemental automatic breast ultrasound (ABUS) demonstrates 7 mm circumscribed slightly hypoechoic circumscribed lesion at 11 o’clock position in right breast. Lesion was classified as BI-RADS 3. Patient has undergone yearly mammograms for 4 years following the ABUS examination with no breast cancer diagnosis.

News | Breast Imaging | July 16, 2021
July 16, 2021 —...
Volpara now holds 98 granted patents across 27 countries
News | Breast Imaging | July 16, 2021
July 16, 2021 — Volpara has recently been granted another patent by the...
Interviews with the 1,000 at-risk patients also led to some interesting conclusions, Fine said. Even in the early days of 3D mammography, most women interviewed had at least heard about the technology.

Getty Images

News | Mammography | July 15, 2021
July 15, 2021 —  For any type of diagnostic test, technology that helps improve the reliability of test results is a